Home » Topics » Regulatory » EMA

EMA
RSS

Obeticholic acid receives E.U. orphan drug status for primary biliary cirrhosis

Aug. 10, 2010

Celgene's pomalidomide receives E.U. orphan drug status for myelofibrosis

Aug. 10, 2010

EMA's CHMP issues positive opinion on Relistor in prefilled syringes

Aug. 6, 2010

COMP recommends orphan drug status for XOMA-052 in Behcet's disease

July 30, 2010

Bionovo moves Menerba to phase III testing in Europe

July 30, 2010

CHMP issues positive opinion on Arixtra use for superficial vein thrombosis

July 27, 2010

CHMP issues positive opinion on Twynsta for hypertension

July 26, 2010

EMA provides update on benefit-to-risk review of Avandia, Avandamet and Avaglim

July 26, 2010

EMA recommends restricting modafinil use

July 26, 2010

CHMP concludes topical ketoprofen has positive benefit-to-risk balance

July 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 7, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...